WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience
QUICK SEARCH:   [advanced]


     
-


HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (220)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dineley, K. T.
Right arrow Articles by Sweatt, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dineley, K. T.
Right arrow Articles by Sweatt, J. D.

 Previous Article  |  Next Article 

The Journal of Neuroscience, June 15, 2001, 21(12):4125-4133

beta -Amyloid Activates the Mitogen-Activated Protein Kinase Cascade via Hippocampal alpha 7 Nicotinic Acetylcholine Receptors: In Vitro and In Vivo Mechanisms Related to Alzheimer's Disease

Kelly T. Dineley1, Marcus Westerman3, Duy Bui1, Karen Bell1, Karen Hsiao Ashe2, 3, and J. David Sweatt1

1 Division of Neuroscience, Baylor College of Medicine, Houston, Texas 77030, and Departments of 2 Neurology and 3 Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Alzheimer's Disease (AD) is the most common of the senile dementias, the prevalence of which is increasing rapidly, with a projected 14 million affected worldwide by 2025. The signal transduction mechanisms that underlie the learning and memory derangements in AD are poorly understood. beta -Amyloid (Abeta ) peptides are elevated in brain tissue of AD patients and are the principal component of amyloid plaques, a major criterion for postmortem diagnosis of the disease. Using acute and organotypic hippocampal slice preparations, we demonstrate that Abeta peptide 1-42 (Abeta 42) couples to the mitogen-activated protein kinase (MAPK) cascade via alpha 7 nicotinic acetylcholine receptors (nAChRs). In vivo elevation of Abeta , such as that exhibited in an animal model for AD, leads to the upregulation of alpha 7 nAChR protein. alpha 7 nAChR upregulation occurs concomitantly with the downregulation of the 42 kDa isoform of extracellular signal-regulated kinase (ERK2) MAPK in hippocampi of aged animals. The phosphorylation state of a transcriptional mediator of long-term potentiation and a downstream target of the ERK MAPK cascade, the cAMP-regulatory element binding (CREB) protein, were affected also. These findings support the model that derangement of hippocampus signal transduction cascades in AD arises as a consequence of increased Abeta burden and chronic activation of the ERK MAPK cascade in an alpha 7 nAChR-dependent manner that eventually leads to the downregulation of ERK2 MAPK and decreased phosphorylation of CREB protein.

Key words: Alzheimer's disease; MAPK; nicotinic receptor; amyloid; kinase; hippocampus; learning; memory


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Alzheimer's Disease (AD) clinically presents itself as impaired memory formation, yet despite intensive study the mechanisms underlying AD-related memory dysfunction remain mysterious. The discovery that soluble beta -amyloid (Abeta ) peptides are elevated in the brains of AD patients raises the issue of whether these molecules play a causative role in AD (Kuo et al., 1996). Abeta peptides are generated from amyloid precursor protein (APP) via endo-proteolytic cleavage by beta - and gamma -secretases (Selkoe, 1998). In normal individuals Abeta 40 comprises the majority of the Abeta population; a far smaller fraction is made up of Abeta 42 (Kuo et al., 1996). Abeta 42 is highly fibrillogenic and exhibits trophic and toxic effects on neurons (Lambert et al., 1998; Hartley et al., 1999; Dodart et al., 2000).

Early onset AD is associated with several risk factors, the best correlated being age and the inheritance of specific genes that result in the increased production of Abeta peptides. Thus several laboratories are seeking to gain insights into AD by studying the effects of Abeta in vitro and in vivo (Hsiao, 1998; Dodart et al., 2000). Studies on transgenic animals that express the human genes linked to early onset familial AD (FAD) have shown that aberrant Abeta production leads to many pathological features of AD (Borchelt, 1998; Hsiao, 1998). One transgenic strain (Tg2576) exhibits several pathological features of AD, including elevated Abeta production with subsequent hippocampus-dependent learning and memory deficits, age-dependent accumulation of Abeta fibrils, and plaque formation (Hsiao et al., 1996; Irizarry et al., 1997a; Chapman et al., 1999). The Tg2576 mouse strain at 9 months of age exhibits learning deficits without neuronal cell loss or Abeta deposition into plaques (Irizarry et al., 1997b). Therefore, the impairments leading to this phenotype are likely in the normal cellular signaling cascades involved in learning and memory.

Using this rationale, we investigated Abeta 42 activation of the extracellular signal-regulated kinase (ERK2) isoform of the ERK mitogen-activated protein kinase (MAPK) cascade, because activation of this kinase in hippocampus is required for contextual and spatial memory formation in mammals (Atkins et al., 1998; Blum et al., 1999; Schafe et al., 1999; Selcher et al., 1999). In addition, we evaluated the phosphorylation state of a downstream target of ERK MAPK in hippocampus, the cAMP-regulatory element binding (CREB) protein, also a necessary component for hippocampus-dependent memory formation in mammals (Bourtchuladze et al., 1994).

The alpha 7 nicotinic acetylcholine receptor (nAChR) is expressed in brain regions particularly susceptible to the ravages of AD, and the functional location of alpha 7 nAChRs in hippocampus indicates a role for these receptors in memory formation (Perry et al., 1995; Frazier et al., 1998; McQuiston and Madison, 1999). Recent studies have shown that Abeta 42 coimmunoprecipitates with the alpha 7 nAChR in samples from postmortem AD hippocampus, and alpha 7 nAChR antagonists compete for Abeta 42 peptide binding to heterologously expressed alpha 7 nAChRs (Wang et al., 2000). Furthermore, preincubation with Abeta 42 peptide antagonizes the activation of alpha 7 nAChR-like currents in hippocampal interneurons (Pettit et al., 2001). Therefore, we tested the hypothesis that the alpha 7 nAChR functions as a receptor for Abeta 42 in the hippocampus, coupling Abeta 42 to the ERK MAPK cascade. Furthermore, in an animal model of AD we evaluated the effects of chronic elevated Abeta on this signal transduction cascade.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Materials. Unless otherwise stated, chemicals and drugs were purchased from Sigma (St. Louis, MO). Synthetic rat Abeta 42 was purchased from Calbiochem (La Jolla, CA). Abeta 42 stock solutions were prepared at 100 µM in 100 mM HEPES, pH 8.5, aliquoted, and stored frozen. Anti-alpha 7 nAChR antibody was purchased from Babco (Richmond, CA). Anti-ERK1/2 and anti-ERK1/2 dually phosphorylated at Thr202/Tyr204 antibodies were purchased from Cell Signaling Technologies. Anti-CREB antibody also was purchased from Cell Signaling Technologies. Anti-CREB phosphorylated at Ser133 antibody was developed and characterized in the laboratory of J. D. Sweatt. Tissue culture mediums and buffers were prepared with supplies from Life Technologies (Gaithersburg, MD).

Animal subjects. Acute hippocampal slices were obtained from mice heterozygous for the L250T alpha 7 nAChR transgene (Orr-Urtreger et al., 2000). Morris water maze testing was performed on Tg2576 mice carrying a human APP transgene with the K670N-M671L mutation (Hsiao et al., 1996). This was followed by a longitudinal biochemical analysis of ERK, CREB, and alpha 7 nAChR levels at 4, 13, and ~20 months of age. Postnatal day 7 (P7), P10, or P13 Sprague Dawley rat pups (Harlan Sprague Dawley, Indianapolis, IN) were used for hippocampal explant cultures. All animal experiments were performed in accordance with the Baylor College of Medicine Institutional Animal Care and Use Committee and with national regulations and policies.

Hippocampus dissection. Animals were decapitated, and both hippocampi were removed and placed into ice-cold cutting solution [containing (in mM) 1.25 NaH2PO4, 28 NaHCO3, 60 NaCl, 3 KCl, 110 sucrose, 0.5 CaCl2, 7 MgCl2, 5 glucose, and 0.6 ascorbate]. For experiments that used alpha 7 nAChR L250T heterozygote animals, 400 µM transverse slices were prepared (see below). For quantitative immunoblot that used samples from Tg2576 mice and age-matched control animals (most often littermates), area CA1 and dentate gyrus (DG) were subdissected from each hippocampus and prepared for quantitative immunoblot as described previously (Roberson et al., 1999). The following numbers of test subjects were used: 4 month Tg2576 animals, n = 10; 13 month animals, n = 8; 18-22 (~20) month animals, n = 20.

Acute hippocampal slice preparation and drug treatments. Transverse hippocampal slices (400 µm) were prepared as described previously (Roberson et al., 1999) from mice heterozygote for the L250T mutation in the alpha 7 nAChR (Orr-Urtreger et al., 2000). Slices were maintained in aCSF [containing (in mM) 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 25 NaHCO3, 2 CaCl2, 1 MgCl2, and 25 glucose] for drug treatments. Slices were incubated in 500 µM nicotine for 10 min with or without pretreatment (for 30 min) with 1 µM MLA. Basal samples represent identical slices that were left untreated. Samples were subjected to quantitative immunoblot as described previously. All experiments included a 10 µM PDA treatment (for 10 min) as a positive control for ERK MAPK activation. Data that are normalized to basal samples are reported as average ± SEM. Experimental results represent replicates of three to five slices per treatment.

Hippocampal slice culture and treatments. Hippocampal slice cultures were prepared from P7, P10, or P13 Sprague Dawley rat pups and maintained in culture according to the method of Stoppini et al. (1991). Then 24 hr before assay the cultures were rinsed and switched into serum-free culture medium (Neurobasal medium, pH 7.2, supplemented with B-27, 1% penicillin-streptomycin, 1.4% 1.8 M glucose, 0.5% 200 mM glutamine, and 0.25 µg/ml Fungizone). After 5-11 d in vitro the slices were assayed for ERK MAPK activation after various treatments. Assays were performed on at least eight slices per treatment in triplicate or greater for each experiment. Basal samples represent identical cultures that were left untreated. Samples were subjected to quantitative immunoblot as described previously. Data that are normalized to basal samples are reported as average ± SEM. Results represent at least three experimental replicates. Treatments were performed in serum-free culture medium and included (1) 500 µM nicotine (for 10 min) with or without pretreatment (for 30 min) with 1 µM MLA; (2) 100 nM Abeta 42 for 2, 5, 10, 30, or 120 min; (3) 5 min incubation with 0.01, 0.1, 1.0, 10, or 100 nM Abeta 42; (4) 5 min incubation with 100 nM Abeta 42 with or without pretreatment (for 30 min) with 1 µM MLA or (for 2 hr) with 100 µM alpha -BTX; (5) 500 µM nicotine (for 10 min) with or without pretreatment (for 2 hr) with 100 nM Abeta 42; (6) 10 µM PDA (for 10 min) with or without pretreatment (for 2 hr) with 100 nM Abeta 42; (7) 100 nM Abeta 42 with or without pretreatment (for 1 hr) with 1 µM TTX; (8) 100 nM Abeta 42 with or without preincubation (for 1 hr) in culture medium containing 5 mM EGTA; (9) 100 pM Abeta 42 treatment for 144 hr. As a positive control for ERK MAPK activation, where relevant, the experiments included a 10 µM PDA treatment (for 10 min).

Quantitative immunoblotting. Harvested brain tissue was sonicated in sonication buffer [containing (in mM) 10 HEPES, pH 7.4, 150 NaCl, 50 NaF, 1 ED/EGTA, 10 Na4P2O7, and 1 Na3VO4 plus 200 nM calyculin A, 10 µg/ml leupeptin, 2 µg/ml aprotinin, and 1 µM microcystin-LR], and protein concentration was determined with BCA (Pierce, Rockford, IL). Samples were subjected to SDS-PAGE and transferred to Immobilon-P (Millipore, Bedford, MA), followed by immunoblotting with the appropriate primary and secondary antibodies and chemiluminescence (ECL, Amersham/Pharmacia Biotech, Piscataway, NJ). Band intensity was quantified with Scion Image software (NIH Image, Bethesda, MD) from film exposures (BioMax, Kodak, Rochester, NY) in the linear range for each antibody and normalized to basal/control level. Normalized basal/control values were determined for each immunoblot by averaging basal/control values, dividing each basal/control and test/transgenic sample density by the average of the basal/control set, and then determining the average and SEM for basal/control and test/transgenic samples.

Spatial learning task. Initially, Tg2576 mice and age-matched control animals underwent cued training for 3 d consecutively (8 trials/d), swimming to a raised black platform marked with a black and white striped pole. The platform location and start quadrant were varied pseudo-randomly in each trial. Hidden platform training was performed over 9 d consecutively (4 trials/d), wherein mice were required to locate within 60 sec a platform submerged 1.5 cm beneath the surface of opaque water. Once the platform was reached in hidden platform training, the mice were allowed to remain on the platform for 30 sec. Mice who failed to reach the platform within 60 sec were led to the platform with a retrieval scoop. At 16-24 hr after the 12th, 24th, and 36th training trials, probe trials were run in which mice swam for 60 sec in the pool with no platform. Trials were monitored by a ceiling-mounted camera above the pool and analyzed with the HVS tracking system (HVS Image Ltd., Hampton, UK). Further analysis was done with Wintrack (kindly provided by Dr. David Wolfer, University of Zurich, Switzerland).

Exclusion criteria omitted mice with obvious swimming difficulties, such as persistent floating, sinking, or abnormal swimming patterns. Mice exhibiting an escape latency >2 SD longer than the age-matched Tg2576 mean during the last four cued trials and mice that consistently failed to orient to or follow the retrieval scoop by the end of the testing period also were excluded from data analysis.

Statistical methods. Student's t test or one-way ANOVA was performed on quantitative immunoblot results, followed by post hoc analysis with the method of Tukey.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

We first tested whether alpha 7 nAChRs could mediate activation of the ERK2 MAPK cascade by treating hippocampal slices with nicotine and assaying for a resultant increase in ERK2 MAPK phosphorylation, a direct indicator of kinase activation (Sturgill et al., 1988; Payne et al., 1991). Because the wild-type alpha 7 nAChR receptor rapidly desensitizes, the slices in these experiments were prepared from the hippocampi of heterozygote transgenic (L250T) animals that contain a targeted mutation in the alpha 7 nAChR gene that renders the expressed alpha 7 nAChRs resistant to desensitization (Revah et al., 1991; Orr-Urtreger et al., 2000). Nicotine activates the 42 kDa ERK2 isoform of MAPK in hippocampi from L250T animals (Fig. 1a). Stimulation of ERK2 activity is dependent on alpha 7 nAChR function because an alpha 7-selective antagonist, methyllycaconitine (MLA), attenuates nicotine-induced activation of ERK2 MAPK in the L250T hippocampal slices. In addition, wild-type rat hippocampal slices maintained in culture exhibit activation of ERK2 MAPK with nicotine treatment that is blocked by MLA pretreatment (Fig. 1b). These results demonstrate that alpha 7 nAChR activation is capable of stimulating ERK2 MAPK in hippocampus.



View larger version (27K):
[in this window]
[in a new window]
  		Figure 1.   Nicotine activation of ERK2 in hippocampal slices is mediated by alpha 7 nAChRs. a, Quantitative immunoblot demonstrates that 500 µM nicotine stimulated ERK2 MAPK activity, which is antagonized by 1 µM MLA in hippocampal slices from mice heterozygous for the L250T alpha 7 nAChR transgene. Basal, 1.00 ± 0.22; nicotine (nic), 2.33 ± 0.13; MLA + nicotine, 1.34 ± 0.14. *Significant difference from basal level; p < 0.01, post hoc Tukey multiple comparison test. Representative immunoblot results are depicted below the response histogram. ERK1 (top band) activation paralleled that of ERK2; however, absolute levels of phospho-ERK1 were far below ERK2 and were not quantified. Slices from wild-type animals did not exhibit significant ERK2 MAPK activation with nicotine treatment, likely because of the rapid desensitization kinetics of wild-type alpha 7 nAChRs precluding biochemical detection of ERK2 MAPK activation (Seguela et al., 1995). b, Quantitative immunoblot demonstrates that ERK2 MAPK activation by nicotine in cultured rat hippocampal slices is blocked by 1 µM MLA. Basal, 1.01 ± 0.08; nicotine, 1.66 ± 0.13; MLA + nicotine, 1.22 ± 0.09. *Denotes nicotine stimulation is significantly different from basal level; p < 0.001, post hoc Tukey multiple comparison test. Representative immunoblot results are depicted below the response histogram.

Hippocampal slice culture technique was used to evaluate whether alpha 7 nAChRs mediate Abeta 42 stimulation of the ERK MAPK cascade. Abeta activates several kinase systems in cultured cells (Saitoh et al., 1993; Kosik et al., 1996), including the ERK MAPK cascade in cultured primary cortical and hippocampal neurons (Ekinci et al., 1999; Rapoport and Ferreira, 2000). The Abeta preparations used in these previous studies varied vis-à-vis the aggregation state and length of the synthetic peptides that were used. Our work used Abeta 42 peptide that was prepared under conditions to promote solubility and to retard aggregation (Burdick et al., 1992; Garzon-Rodriguez et al., 1997). We tested our Abeta 42 preparations for aggregation in a Congo red assay. At the concentrations used and under the incubation conditions tested, none of the Abeta 42 preparations significantly pelleted out of solution with Congo red dye at 2.5 or 25 µM (Brining, 1997) (data not shown). We found that synthetic Abeta 42 activates ERK2 MAPK in cultured hippocampal slices at concentrations typically found in the CSF and brains of AD patients and in animal models of AD (Hsiao et al., 1996; Andreasen et al., 1999a,b; Tapiola et al., 2000) (Fig. 2a). Furthermore, ERK2 MAPK activation occurs rapidly and decreases with prolonged exposure to Abeta 42, indicative of receptor or MAPK cascade desensitization (Fig. 2b).



View larger version (21K):
[in this window]
[in a new window]
  		Figure 2.   Time course and concentration dependence of Abeta 42 activation of ERK2 MAPK in cultured rat hippocampal slices. a, Abeta 42 activates ERK MAPK in the picomolar to nanomolar range. Data points are as follows: 0 nM (1.00 ± 0.15), 0.01 (0.98 ± 0.16), 0.1 (1.98 ± 0.48), 1.0 (1.74 ± 0.25), 10 (2.70 ± 0.62), and 100 (2.01 ± 0.30) nM Abeta 42 for 5 min. Representative immunoblot results are depicted below the response curve. b, The 100 nM Abeta 42 rapidly activates ERK2 MAPK in rat hippocampal slice cultures. Peak response occurs at 5 min Abeta 42 and returns to baseline within 2 hr. Data points are as follows: 2 (1.88 ± 0.30), 5 (3.92 ± 1.15), 10 (2.61 ± 0.83), 30 (1.81 ± 0.44), and 120 (1.34 ± 0.17) min. *Significant difference from basal level (1.06 ± 0.12); p < 0.05, Student's t test with Welch's correction because variances differ significantly according to Bartlett's test. Representative immunoblot results are depicted below the response curve.

Stimulation of ERK2 MAPK activity with Abeta 42 in cultured rat hippocampal slices is blocked by the alpha 7 nAChR antagonists MLA and alpha -bungarotoxin (BTX), demonstrating that alpha 7 nAChR function is necessary for Abeta 42 coupling to the ERK MAPK cascade (Fig. 3a). This was also the case for acute hippocampal slices prepared from L250T animals and exposed to identical drug treatments (data not shown). Cross-desensitization is one way to test the possibility that two different agonists couple via the same receptor type. Pretreatment of cultured hippocampal slices with Abeta 42 blocked nicotine stimulation of ERK MAPK activity, evidence that nicotine and Abeta 42 mediate their effects on ERK2 MAPK via the same receptor type (Fig. 3b). Abeta 42 pretreatment of cultured slices did not interfere with the ability of phorbol 12,13-dibutyrate (PDA) to activate ERK MAPK, demonstrating that the MAPK cascade was not desensitized by Abeta 42 treatment, evidence in support of alpha 7 nAChRs mediating this Abeta 42 effect (Fig. 3c). We tested whether action potential generation is necessary for the ERK2 MAPK activation by Abeta 42 by including tetrodotoxin (TTX) in the assay medium. TTX alone decreased the basal level of ERK MAPK activation, indicating that endogenous synaptic transmission in the hippocampal slice cultures contributes to basal ERK2 MAPK activity level. Abeta 42 in the presence of TTX results in significant ERK2 MAPK activation as compared with cultures treated with TTX alone (Fig. 3d). Because alpha 7 nAChRs are highly permeable to Ca2+ (Seguela et al., 1993), we tested the Ca2+ dependency of Abeta 42-induced ERK MAPK activation. Depleting the assay system of external Ca2+ by including EGTA in the culture medium blocks Abeta 42-induced activation of ERK2 MAPK (Fig. 3d). Overall, our experiments show that Abeta 42 rapidly activates ERK2 MAPK in hippocampus for which alpha 7 nAChR function is necessary. This activation uses extracellular Ca2+ (likely via alpha 7 nAChRs directly and alpha 7 nAChR-dependent depolarization) and is action potential-independent; the ability of Abeta 42 to activate ERK2 MAPK exhibits desensitization without inhibiting phorbol ester activation of the cascade. Furthermore, ERK MAPK activation occurs in response to picomolar and nanomolar concentrations of Abeta 42.



View larger version (43K):
[in this window]
[in a new window]
  		Figure 3.   alpha 7 couples Abeta 42 activation of ERK2 MAPK in cultured rat hippocampal slices. a, Quantitative immunoblot demonstrates that ERK2 MAPK activation by 100 nM Abeta 42 is blocked by 1 µM MLA and 100 µM BTX. Basal, 1.00 ± 0.04; Abeta 42 (light-shaded bar), 1.58 ± 0.09; MLA + Abeta 42, 1.19 ± 0.07; Abeta 42 (dark-shaded bar), 1.67 ± 0.11; BTX + Abeta 42, 0.94 ± 0.14. *Significant difference from basal ERK2 MAPK activity; p < 0.0001, Student's t test with Welch's correction because variances differ significantly according to Bartlett's test. Representative immunoblot results are depicted below the response histogram. b, Abeta 42 (100 nM) desensitizes the nicotine-induced (500 µM) activation of ERK2 MAPK. Basal, 1.05 ± 0.14; nicotine (nic), 1.94 ± 0.22; Abeta 42 (at 2 hr), 1.14 ± 0.24; Abeta 42 + nicotine (at 2 hr), 1.03 ± 0.13. *Significant difference from basal ERK2 MAPK activity; p < 0.001, post hoc Tukey multiple comparison test. Representative immunoblot results are depicted below the response histogram. c, Abeta 42 (100 nM) does not desensitize the PDA-induced (10 µM) activation of ERK2 MAPK. Basal, 1.00 ± 0.08; Abeta 42 (at 2 hr), 0.78 ± 0.11; Abeta 42 + PDA (at 2 hr), 2.15 ± 0.54; PDA, 2.25 ± 0.13. *Significant difference from basal ERK2 MAPK activity; p < 0.01, post hoc Tukey multiple comparison test. Representative immunoblot results are depicted below the response histogram. d, The 100 nM Abeta 42 activation of ERK2 MAPK is not blocked by TTX and exhibits Ca2+ dependency. Basal, 1.00 ± 0.06; Abeta 42, 1.30 ± 0.07; TTX, 0.67 ± 0.10; Abeta 42 + TTX, 1.02 ± 0.05; EGTA, 0.59 ± 0.04; Abeta 42 + EGTA, 0.65 ± 0.05. *Significant difference from basal-induced ERK2 MAPK activity. #, Significant difference from TTX-induced ERK2 MAPK activity; p < 0.001, post hoc Tukey multiple comparison test.

As a complement to these in vitro experiments, we investigated the effects of elevated Abeta in vivo. We used Tg2576 animals to evaluate the long-term effects of elevated Abeta on hippocampal alpha 7 nAChR expression level and ERK2 MAPK activity. A typical consequence of chronic exposure to nAChR agonist is nAChR upregulation (Marks et al., 1983; Fenster et al., 1999). We therefore hypothesized that alpha 7 nAChRs would be upregulated in Tg2576 hippocampus as a consequence of chronic exposure to Abeta . We found an age-dependent increase in alpha 7 nAChR protein in the hippocampi of these animals as compared with age-matched controls (Fig. 4a,b). This increase is detected as early as 4 months of age in dentate gyrus (DG). With age, alpha 7 nAChR protein continues to increase in the DG as well as in area CA1. As a control, we measured the level of another subtype of nAChR subunit, the alpha 4 subunit, and found no significant increase in alpha 4 nAChR protein in the hippocampi of Tg2576 animals (data not shown). Thus our data demonstrate a selective age-dependent upregulation of alpha 7 nAChR in the hippocampus of Tg2576 mice. An explanation for these data in light of our findings in vitro is that alpha 7 nAChRs in the hippocampi of Tg2576 animals are stimulated chronically by Abeta , leading to desensitization and upregulation of alpha 7 nAChRs.



View larger version (26K):
[in this window]
[in a new window]
  		Figure 4.   alpha 7 nAChR is upregulated in hippocampus and DG of Tg2576 mice. a, Quantitative immunoblot of area CA1 and DG from 4, 13, and ~20 month Tg2576 hippocampus reveals upregulation of alpha 7 nAChR protein as early as 4 months. *Significantly higher alpha 7 nAChR level than age-matched control animals (p < 0.03) by Student's t test. Dashed line represents normalized control animal level; note the change in scale for ~20 month animals. Filled bar, CA1; shaded bar, DG. b, Representative immunoblot for alpha 7 nAChR level in Tg2576 and age-matched control animals.

Given the necessity for ERK2 MAPK activity in certain forms of learning and memory, the finding that Abeta 42 activates ERK MAPK via alpha 7 nAChRs, and the observation that alpha 7 nAChRs are upregulated in Abeta -overexpressing mice, we determined whether the ERK MAPK cascade is disrupted in Tg2576 hippocampus. Quantitative immunoblot reveals that ERK2 phosphorylation is increased significantly in Tg2576 hippocampus as compared with controls (Fig. 5a,c, Table 1). In area CA1 at 13 months and in DG at 4 and 13 months, ERK2 MAPK hyperactivation is detected. These results correlate with elevated alpha 7 nAChR protein in these brain regions as was described above. By 20 months of age ERK2 MAPK is downregulated; the hyperactivation detected at earlier ages is absent in DG and is below control animal levels in area CA1. At this age total ERK2 MAPK protein is unchanged in DG, whereas in area CA1 both total ERK2 MAPK protein and activity are downregulated by 22 and 27%, respectively. Previous evidence suggests that this level of reduction in ERK2 MAPK activity in hippocampus can lead to learning and memory impairments. For example, Selcher et al. (1999) have shown that partial inhibition of ERK2 MAPK activity in hippocampus blocks two forms of hippocampus-dependent learning in the mouse.



View larger version (34K):
[in this window]
[in a new window]
  		Figure 5.   Downstream targets of alpha 7 nAChR activation in Tg2576 hippocampus exhibit dysregulation. ERK2 and CREB proteins undergo hyperactivation, followed by downregulation, as compared with age-matched control animals. Differences between Tg2576 and age-matched control animals were detected by quantitative immunoblot of area CA1 and DG from 4, 13, and ~20 month Tg2576 hippocampus. Samples were evaluated for total and phospho-ERK2 MAPK (a, c) and total and phospho-CREB (b, d) levels in CA1 and DG, respectively. *Significant difference from age-matched control animal level (p <=  0.05) by Student's t test. Dashed line represents normalized control animal level. Filled bar, Total; shaded bar, phospho.


                              
View this table:
[in this window]
[in a new window]
  		Table 1.   Data summary for the parameters measured in hippocampi of Tg2576 mice at different ages as compared with age-matched control animals

Because ERK MAPK is altered in the hippocampi of Tg2576 animals, it is of interest to learn whether downstream targets of this kinase cascade also are affected. CREB is phosphorylated at Ser133 by rsk2, a kinase that is activated by ERK MAPK phosphorylation (Xing et al., 1996). We evaluated the phosphorylation state and total protein level of CREB protein in CA1 and DG of Tg2576 hippocampi by quantitative immunoblotting (Fig. 5b,d, Table 1). In Tg2576 hippocampus, CREB phosphorylation is elevated at 13 months, followed by downregulation by 20 months of age. In area CA1, CREB phosphorylation fluctuates with ERK2 MAPK activity, consistent with CREB phosphorylation being coupled to the ERK MAPK cascade (Roberson and Sweatt, 1996; Impey et al., 1998; Watabe et al., 2000). CREB protein level was not altered significantly in area CA1. These data demonstrate that, in area CA1, derangements of the ERK MAPK cascade occur in conjunction with dysregulation of a downstream target, the transcriptional regulator CREB. In DG, however, CREB protein level is elevated at 13 and 20 months of age, indicative of differential regulation of CREB in DG versus area CA1. Furthermore, the correlated CREB phosphorylation with ERK2 activation was not observed in DG, although coupling between ERK MAPK activity and CREB phosphorylation at Ser133 in this region has been demonstrated (Davis et al., 2000).

Tg2576 animals exhibit long-term potentiation (LTP) and working memory deficits by 9 months of age and a spatial learning impairment that is evident at 6 months, which deteriorates further at 20-26 months of age (M. Westerman and K. H. Ashe, personal communication). We tested whether the increased alpha 7 nAChR protein we observed correlated with behavioral learning defects in these animals. Before biochemical analysis, Tg2576 and control animals were trained and tested in the Morris water maze. A scatter plot of the alpha 7 nAChR levels of individual animals versus the percentage of time spent in the target quadrant during a third probe trial in the Morris water maze illustrates a negative correlation (R2 = -0.283 and -0.193; p <=  0.05, for CA1 and DG, respectively) between alpha 7 nAChR level and Morris water maze performance (Fig. 6). These data do not indicate a simple linear correlation between alpha 7 nAChR protein levels and Morris water maze performance. However, these observations are consistent with the idea that alpha 7 nAChR upregulation in hippocampus may serve as a biochemical marker for the synaptic plasticity derangement and learning and memory deficits in Tg2576 animals.



View larger version (14K):
[in this window]
[in a new window]
  		Figure 6.   Animals with elevated alpha 7 nAChR level fail to perform to criteria in the Morris water maze. Scatter plot of the third probe trial performance of individual ~20-month-old Tg2576 and control animals versus alpha 7 nAChR protein levels in CA1 and DG. Dashed line indicates performance criterion. Filled squares, Control; filled diamonds, Tg.

We further tested the hypothesis that chronic exposure to Abeta 42 leads to alpha 7 nAChR upregulation in hippocampus by incubating cultured hippocampal slices with 100 pM Abeta 42 for 6 d. After 144 hr of Abeta exposure, alpha 7 nAChR protein was increased by over twofold (Fig. 7). Treated slices had the same appearance as control slices after 9 d in culture. These data demonstrate that prolonged exposure in vitro to a concentration of Abeta found in the brains of AD patients and Tg2576 animals leads to alpha 7 nAChR upregulation in hippocampal tissue.



View larger version (31K):
[in this window]
[in a new window]
  		Figure 7.   Chronic exposure to Abeta 42 leads to increased alpha 7 nAChR protein in hippocampal slice cultures. Cultured rat hippocampal slices were exposed to 100 pM Abeta 42 for 144 hr, and alpha 7 nAChR protein was quantified by immunoblot. The data that are expressed are normalized to the alpha 7 nAChR protein level in cultures that were left untreated. Representative immunoblot results are shown below the histogram. *Significant difference from control level (p < 0.0001) by Student's t test. Basal, 1.00 ± 0.11; Abeta 42-treated, 2.35 ± 0.13.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

We have demonstrated that the alpha 7 nAChR couples Abeta 42 to the ERK2 MAPK cascade in hippocampus, uses Ca2+, and is independent of action potential propagation. We found that, in vitro, concentrations of Abeta 42 that occur in the CSF and brain of AD patients rapidly activate hippocampal ERK2 MAPK and lead to alpha 7 nAChR upregulation with chronic exposure. The experiments performed in this study do not address directly whether the alpha 7 nAChR is a receptor for Abeta 42. However, the following observations are consistent with this idea: (1) extended exposure of cultured rat hippocampal slices to Abeta 42 blocks subsequent alpha 7 nAChR agonist activation of ERK2 MAPK (under these conditions the ERK MAPK cascade is not desensitized to activation by phorbol ester); (2) both MLA and BTX block Abeta 42 activation of ERK2 MAPK; (3) TTX does not block Abeta 42 activation of ERK2 MAPK. Furthermore, ERK2 MAPK activation by Abeta 42 requires Ca2+ influx, which is consistent with the model that Ca2+ influx via alpha 7 nAChRs and alpha 7 nAChR-dependent depolarization-induced Ca2+ influx leads to ERK2 MAPK activation. We favor the interpretation that Abeta 42 is an agonist for alpha 7 nAChRs in hippocampus and that prolonged exposure to Abeta can elicit alpha 7 nAChR upregulation as a result of chronic receptor stimulation, a typical phenomenon after chronic nAChR agonist exposure (Marks et al., 1983; Fenster et al., 1999). In turn, we hypothesize that prolonged exposure of alpha 7 nAChRs to Abeta leads to chronic stimulation of ERK2 MAPK.

As predicted by our in vitro findings, we observed effects on alpha 7 nAChR and ERK2 MAPK in the hippocampus of a transgenic mouse line that overproduces Abeta peptides (Hsiao et al., 1996). In the hippocampi of these animals alpha 7 nAChR protein increases in an age-dependent manner, whereas the basal activation state of ERK2 MAPK exhibits an age-dependent hyperactivation followed by downregulation. ERK2 MAPK hyperactivation is coincident with alpha 7 nAChR upregulation at young ages; one interpretation of these data is that, in these animals, Abeta chronically stimulates the ERK MAPK cascade via alpha 7 nAChRs. Likewise, the phosphorylation state of CREB, a downstream effector of the ERK MAPK cascade in area CA1, parallels the changes measured in ERK2 MAPK in this region. Thus, in Tg2576 animals and, we hypothesize in AD as well, elevated Abeta has profound effects on an Abeta receptor (alpha 7 nAChR) and a signal transduction cascade (ERK MAPK) to which it is coupled. In older Tg2576 animals the pronounced upregulation of alpha 7 nAChRs is associated with the downregulation of ERK2 MAPK.

Exposure of hippocampal slices to Abeta 42 triggers signal transduction events that are important for hippocampal synaptic plasticity and learning and memory; activation of the ERK2 MAPK cascade in vitro by Abeta 42 requires alpha 7 nAChR function. These findings are consistent with the concept that alpha 7 nAChR is an Abeta 42 receptor. There is an emerging literature implicating the alpha 7 nAChR in AD pathophysiology and memory loss. Evidence complementing our data that Abeta 42 signals via the alpha 7 nAChR includes the previous observations that (1) alpha 7 nAChRs coimmunoprecipitate from postmortem human AD hippocampus; (2) Abeta peptides compete alpha 7 agonist and antagonist binding to SK-N-MC cells; (3) 20-fold more alpha 7 nAChR protein immunoprecipitates with Abeta 42 from AD hippocampus as compared with control; (4) preincubation with Abeta 42 antagonizes an alpha 7 nAChR-like current in hippocampal interneurons; and (5) nicotine protects SK-N-MC cells from neurotoxicity induced by prolonged exposure to Abeta 42 (Kihara et al., 1997; Wang et al., 2000). These last two observations are akin to the cross-desensitization of Abeta 42 and nicotine demonstrated in this study. It must be emphasized, however, that additional Abeta receptors that play important roles in AD etiology are likely (Yan et al., 1996).

What then are the consequences of alpha 7 nAChR coupling Abeta 42 to the ERK MAPK cascade in AD? Our findings suggest that early AD etiology involves chronic activation of the ERK MAPK cascade as a consequence of elevated Abeta binding to and activating this signaling cascade via alpha 7 nAChRs and that these events are concomitant with alpha 7 nAChR upregulation and derangement of ERK2 MAPK signaling. Abeta burden is emerging as an early indicator of cognitive decline in AD in that total Abeta (nonaggregate and aggregates in diffuse or mature senile plaques combined) in the brains of elderly patients correlates with recent premorbid Clinical Dementia Rating scale values, even in the absence of severe dementia (Cummings and Cotman, 1995; Cummings et al., 1996; Naslund et al., 2000). Moreover, CSF Abeta is elevated to nanomolar level in patients with short disease duration and mild cognitive impairment (Nakamura et al., 1994; Tapiola et al., 2000). These findings support the idea that extracellular Abeta levels are elevated in at-risk individuals before gross plaque deposition and severe cognitive impairment. According to our findings, one consequence of nanomolar Abeta in the extracellular milieu of AD brain is the (chronic) activation of the ERK2 MAPK cascade via alpha 7 nAChRs, leading to upregulation of this receptor type. In fact, we have demonstrated in vitro that chronic exposure to Abeta 42 leads to increased alpha 7 nAChR protein in hippocampus. An interesting implication of this hypothesis is that alpha 7 nAChR-selective radioimaging techniques may be useful as a diagnostic test for early AD or risk for AD (Nordberg, 1999; Scheffel et al., 2000).

The ERK2 MAPK cascade is known to play a critical role in hippocampus synaptic plasticity and learning. In area CA1 of the rodent hippocampus ERK2 MAPK is necessary for the expression of a late phase of LTP (English and Sweatt, 1997; Impey et al., 1998; Selcher et al., 1999) and is an important pathway through which neurotransmitters modulate LTP induction (Roberson et al., 1999; Winder et al., 1999; Watabe et al., 2000). Furthermore, ERK2 MAPK activation is necessary for both contextual fear conditioning and escape training in the Morris water maze, both hippocampus-dependent associative learning paradigms (Atkins et al., 1998; Blum et al., 1999; Selcher et al., 1999). Tg2576 animals, in which Abeta production is elevated, exhibit deficits in hippocampus LTP, working memory, and escape training in the Morris water maze (Hsiao et al., 1996; Chapman et al., 1999). On the basis of our findings, we propose a mechanism linking Abeta overproduction to memory dysfunction; specifically, our data suggest that memory deficits occur in part via Abeta 42 eliciting downstream derangements in ERK MAPK signaling. Abeta 42 impinging on the ERK MAPK cascade suggests a molecular basis for the disruptions in memory formation accompanying AD, because the proper functioning of the ERK MAPK cascade is critical for certain types of memory formation.

Our model for the signal transduction events underlying AD etiology posits that elevated Abeta , such as occurs in humans genetically predisposed to the disease, chronically stimulates the ERK MAPK cascade via alpha 7 nAChRs. Chronic exposure to Abeta leads to upregulation of alpha 7 nAChRs and hyperactivation, followed by downregulation of ERK2 MAPK as well as perturbed functionality of downstream targets of this kinase. This derangement of the ERK MAPK signaling cascade may underlie the learning and memory deficits attributed to hippocampal dysfunction in AD. An additional site of action is likely to be disruption of the normal function of the hippocampal circuit, specifically the altered excitability of pyramidal neurons because alpha 7 nAChRs located on GABAergic interneurons can regulate hippocampal pyramidal neuron excitability (Freund et al., 1988, 1990; Frazier et al., 1998). Modifications of GABAergic signaling to area CA1 pyramidal neurons in the hippocampi of animals in which Abeta production is either enhanced or genetically knocked-out have been demonstrated (Fitzjohn et al., 2000; Zaman et al., 2000). Overall, these findings highlight a potential therapeutic target for AD: the alpha 7 nAChR.

In addition to assuaging the MAPK signaling derangement we have described, alpha 7 nAChR antagonist therapy might benefit other aspects of AD etiology such as the selective loss of cholinergic inputs to the hippocampus and cortex as well as effects on Abeta production itself. The cholinergic input to the hippocampus and cortex is a particularly vulnerable neural circuit in AD, and alpha 7 nAChRs are expressed on these projection neurons from the basal forebrain (Arendt et al., 1985; Breese et al., 1997). Our data suggest the possibility that Abeta 42 binding to presynaptic alpha 7 nAChRs may elicit cholinergic fiber loss, and alpha 7 nAChR antagonism might delay this aspect of neurodegeneration in AD.

Finally, although the molecular basis for Abeta overproduction that is a consequence of FAD-linked gene inheritance is not understood, the ERK MAPK cascade has been implicated in regulating Abeta production in neurons (Mills et al., 1997). One of the effects of downregulated ERK2 MAPK activity may be the setting up of a positive feedback loop for Abeta accumulation; blocking the derangement of MAPK signaling via the alpha 7 nAChR thus may alleviate one stimulant of Abeta production. Overall, the findings presented here provide insights into the molecular basis of Abeta -induced pathology and advance the possibilities for treatment targets in AD.


    FOOTNOTES

Received Feb. 1, 2001; revised March 13, 2001; accepted March 14, 2001.

This work was supported by awards to J.D.S. from the National Institute on Aging (NIA), National Institute of Mental Health, National Alliance for Research on Schizophrenia and Depression, and the Texas Advanced Technology Program; an NIA National Research Service Award to K.T.D.; and a National Institute of Neurological Disorders and Stroke award to J.W.P. We thank Drs. James W. Patrick and Daniel H. S. Lee for helpful discussions during the preparation of this manuscript.

Correspondence should be addressed to Kelly T. Dineley or J. David Sweat, Division of Neuroscience, Room S603, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030. E-mail: kdineley{at}cns.bcm.tmc.edu or david{at}cns.bcm.tmc.edu.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

  • Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K (1999a) Cerebrospinal fluid beta -amyloid (1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease [see comments]. Arch Neurol 56:673-680[Abstract/Free Full Text].
  • Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, Blennow K (1999b) Cerebrospinal fluid tau and Abeta 42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 273:5-8[Web of Science][Medline].
  • Arendt T, Bigl V, Tennstedt A, Arendt A (1985) Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in Alzheimer's disease. Neuroscience 14:1-14[Web of Science][Medline].
  • Atkins CM, Selcher JC, Petraitis JJ, Trzaskos JM, Sweatt JD (1998) The MAPK cascade is required for mammalian associative learning. Nat Neurosci 1:602-609[Web of Science][Medline].
  • Blum S, Moore AN, Adams F, Dash PK (1999) A mitogen-activated protein kinase cascade in the CA1/CA2 subfield of the dorsal hippocampus is essential for long-term spatial memory. J Neurosci 19:3535-3544[Abstract/Free Full Text].
  • Borchelt DR (1998) Inherited neurodegenerative diseases and transgenic models. Lab Anim Sci 48:604-610[Medline].
  • Bourtchuladze R, Frenguelli B, Blendy J, Cioffi D, Schutz G, Silva AJ (1994) Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element binding protein. Cell 79:59-68[Web of Science][Medline].
  • Breese CR, Adams C, Logel J, Drebing C, Rollins Y, Barnhart M, Sullivan B, Demasters BK, Freedman R, Leonard S (1997) Comparison of the regional expression of nicotinic acetylcholine receptor alpha 7 mRNA and [125I]-alpha -bungarotoxin binding in human postmortem brain. J Comp Neurol 387:385-398[Web of Science][Medline].
  • Brining SK (1997) Predicting the in vitro toxicity of synthetic beta -amyloid (1-40). Neurobiol Aging 18:581-589[Medline].
  • Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, Yates J, Cotman C, Glabe C (1992) Assembly and aggregation properties of synthetic Alzheimer's alpha 4/beta -amyloid peptide analogs. J Biol Chem 267:546-554[Abstract/Free Full Text].
  • Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, Younkin L, Good MA, Bliss TV, Hyman BT, Younkin SG, Hsiao KK (1999) Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 2:271-276[Web of Science][Medline].
  • Cummings BJ, Cotman CW (1995) Image analysis of beta -amyloid load in Alzheimer's disease and relation to dementia severity. Lancet 346:1524-1528[Web of Science][Medline].
  • Cummings BJ, Pike CJ, Shankle R, Cotman CW (1996) beta -Amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease [see comments]. Neurobiol Aging 17:921-933[Web of Science][Medline].
  • Davis S, Vanhoutte P, Pages C, Caboche J, Laroche S (2000) The MAPK/ERK cascade targets both Elk-1 and cAMP response element-binding protein to control long-term potentiation-dependent gene expression in the dentate gyrus in vivo. J Neurosci 20:4563-4572[Abstract/Free Full Text].
  • Dodart JC, Mathis C, Ungerer A (2000) The beta -amyloid precursor protein and its derivatives: from biology to learning and memory processes. Rev Neurosci 11:75-93[Web of Science][Medline].
  • Ekinci FJ, Malik KU, Shea TB (1999) Activation of the L voltage-sensitive calcium channel by mitogen-activated protein (MAP) kinase following exposure of neuronal cells to beta -amyloid. MAP kinase mediates beta -amyloid-induced neurodegeneration. J Biol Chem 274:30322-30327[Abstract/Free Full Text].
  • English JD, Sweatt JD (1997) A requirement for the mitogen-activated protein kinase cascade in hippocampal long-term potentiation. J Biol Chem 272:19103-19106[Abstract/Free Full Text].
  • Fenster CP, Whitworth TL, Sheffield EB, Quick MW, Lester RA (1999) Upregulation of surface alpha 4beta 2 nicotinic receptors is initiated by receptor desensitization after chronic exposure to nicotine. J Neurosci 19:4804-4814[Abstract/Free Full Text].
  • Fitzjohn SM, Morton RA, Kuenzi F, Davies CH, Seabrook GR, Collingridge GL (2000) Similar levels of long-term potentiation in amyloid precursor protein: null and wild-type mice in the CA1 region of picrotoxin-treated slices. Neurosci Lett 288:9-12[Medline].
  • Frazier CJ, Rollins YD, Breese CR, Leonard S, Freedman R, Dunwiddie TV (1998) Acetylcholine activates an alpha -bungarotoxin-sensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells. J Neurosci 18:1187-1195[Abstract/Free Full Text].
  • Freund RK, Jungschaffer DA, Collins AC, Wehner JM (1988) Evidence for modulation of GABAergic neurotransmission by nicotine. Brain Res 453:215-220[Medline].
  • Freund RK, Luntz-Leybman V, Collins AC (1990) Nicotine interferes with GABA-mediated inhibitory processes in mouse hippocampus. Brain Res 527:286-291[Medline].
  • Garzon-Rodriguez W, Sepulveda-Becerra M, Milton S, Glabe CG (1997) Soluble amyloid Abeta (1-40) exists as a stable dimer at low concentrations. J Biol Chem 272:21037-21044[Abstract/Free Full Text].
  • Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ (1999) Protofibrillar intermediates of amyloid-beta protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19:8876-8884[Abstract/Free Full Text].
  • Hsiao K (1998) Transgenic mice expressing Alzheimer amyloid precursor proteins. Exp Gerontol 33:883-889[Web of Science][Medline].
  • Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice [see comments]. Science 274:99-102[Abstract/Free Full Text].
  • Impey S, Obrietan K, Wong ST, Poser S, Yano S, Wayman G, Deloulme JC, Chan G, Storm DR (1998) Cross talk between ERK and PKA is required for Ca2+ stimulation of CREB-dependent transcription and ERK nuclear translocation. Neuron 21:869-883[Web of Science][Medline].
  • Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT (1997a) APPSw transgenic mice develop age-related Abeta deposits and neuropil abnormalities, but no neuronal loss in CA1 [see comments]. J Neuropathol Exp Neurol 56:965-973[Web of Science][Medline].
  • Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT (1997b) Abeta deposition is associated with neuropil changes, but not with overt neuronal loss, in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 17:7053-7059[Abstract/Free Full Text].
  • Kihara T, Shimohama S, Sawada H, Kimura J, Kume T, Kochiyama H, Maeda T, Akaike A (1997) Nicotinic receptor stimulation protects neurons against beta -amyloid toxicity. Ann Neurol 42:159-163[Web of Science][Medline].
  • Kosik KS, Qiu WQ, Greenberg S (1996) Cellular signaling pathways and cytoskeletal organization. Ann NY Acad Sci 777:114-120[Medline].
  • Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE (1996) Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271:4077-4081[Abstract/Free Full Text].
  • Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from Abeta 1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448-6453[Abstract/Free Full Text].
  • Marks MJ, Burch JB, Collins AC (1983) Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J Pharmacol Exp Ther 226:817-825[Free Full Text].
  • McQuiston AR, Madison DV (1999) Nicotinic receptor activation excites distinct subtypes of interneurons in the rat hippocampus. J Neurosci 19:2887-2896[Abstract/Free Full Text].
  • Mills J, Laurent Charest D, Lam F, Beyreuther K, Ida N, Pelech SL, Reiner PB (1997) Regulation of amyloid precursor protein catabolism involves the mitogen-activated protein kinase signal transduction pathway. J Neurosci 17:9415-9422[Abstract/Free Full Text].
  • Nakamura T, Shoji M, Harigaya Y, Watanabe M, Hosoda K, Cheung TT, Shaffer LM, Golde TE, Younkin LH, Younkin SG (1994) Amyloid-beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease. Ann Neurol 36:903-911[Web of Science][Medline].
  • Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD (2000) Correlation between elevated levels of amyloid beta -peptide in the brain and cognitive decline [see comments]. JAMA 283:1571-1577[Abstract/Free Full Text].
  • Nordberg A (1999) PET studies and cholinergic therapy in Alzheimer's disease. Rev Neurol (Paris) 155:S53-S63.
  • Orr-Urtreger A, Broide RS, Kasten MR, Dang H, Dani JA, Beaudet AL, Patrick JW (2000) Mice homozygous for the L250T mutation in the alpha 7 nicotinic acetylcholine receptor show increased neuronal apoptosis and die within 1 day of birth. J Neurochem 74:2154-2166[Web of Science][Medline].
  • Payne DM, Rossomando AJ, Martino P, Erickson AK, Her JH, Shabanowitz J, Hunt DF, Weber MJ, Sturgill TW (1991) Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). EMBO J 10:885-892[Web of Science][Medline].
  • Perry EK, Morris CM, Court JA, Cheng A, Fairbairn AF, McKeith IG, Irving D, Brown A, Perry RH (1995) Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia, and Alzheimer's disease: possible index of early neuropathology. Neuroscience 64:385-395[Web of Science][Medline].
  • Pettit DL, Shao Z, Yakel JL (2001) beta -Amyloid 1-42 peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci 21:RC120.
  • Rapoport M, Ferreira A (2000) PD98059 prevents neurite degeneration induced by fibrillar beta -amyloid in mature hippocampal neurons. J Neurochem 74:125-133[Web of Science][Medline].
  • Revah F, Bertrand D, Galzi JL, Devillers-Thiery A, Mulle C, Hussy N, Bertrand S, Ballivet M, Changeux JP (1991) Mutations in the channel domain alter desensitization of a neuronal nicotinic receptor. Nature 353:846-849[Medline].
  • Roberson ED, Sweatt JD (1996) Transient activation of cyclic AMP-dependent protein kinase during hippocampal long-term potentiation. J Biol Chem 271:30436-30441[Abstract/Free Full Text].
  • Roberson ED, English JD, Adams JP, Selcher JC, Kondratick C, Sweatt JD (1999) The mitogen-activated protein kinase cascade couples PKA and PKC to cAMP response element binding protein phosphorylation in area CA1 of hippocampus. J Neurosci 19:4337-4348[Abstract/Free Full Text].
  • Saitoh T, Horsburgh K, Masliah E (1993) Hyperactivation of signal transduction systems in Alzheimer's disease. Ann NY Acad Sci 695:34-41[Medline].
  • Schafe GE, Nadel NV, Sullivan GM, Harris A, LeDoux JE (1999) Memory consolidation for contextual and auditory fear conditioning is dependent on protein synthesis, PKA, and MAP kinase. Learn Mem 6:97-110[Abstract/Free Full Text].
  • Scheffel U, Horti AG, Koren AO, Ravert HT, Banta JP, Finley PA, London ED, Dannals RF (2000) 6-[18F]fluoro-A-85380: an in vivo tracer for the nicotinic acetylcholine receptor. Nucl Med Biol 27:51-56[Medline].
  • Seguela P, Wadiche J, Dineley-Miller K, Dani JA, Patrick JW (1993) Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J Neurosci 13:596-604[Abstract].
  • Selcher JC, Atkins CM, Trzaskos JM, Paylor R, Sweatt JD (1999) A necessity for MAP kinase activation in mammalian spatial learning. Learn Mem 6:478-490[Abstract/Free Full Text].
  • Selkoe DJ (1998) The cell biology of beta -amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 8:447-453[Web of Science][Medline].
  • Stoppini L, Buchs PA, Muller D (1991) A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 37:173-182[Web of Science][Medline].
  • Sturgill TW, Ray LB, Erikson E, Maller JL (1988) Insulin-stimulated MAP-2 kinase phosphorylates and activates ribosomal protein S6 kinase II. Nature 334:715-718[Medline].
  • Tapiola T, Pirttila T, Mikkonen M, Mehta PD, Alafuzoff I, Koivisto K, Soininen H (2000) Three-year follow-up of cerebrospinal fluid tau, beta -amyloid 42 and 40 concentrations in Alzheimer's disease. Neurosci Lett 280:119-122[Web of Science][Medline].
  • Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB (2000) beta -Amyloid (1-42) binds to alpha 7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 275:5626-5632[Abstract/Free Full Text].
  • Watabe AM, Zaki PA, O'Dell TJ (2000) Coactivation of beta -adrenergic and cholinergic receptors enhances the induction of long-term potentiation and synergistically activates mitogen-activated protein kinase in the hippocampal CA1 region. J Neurosci 20:5924-5931[Abstract/Free Full Text].
  • Winder DG, Martin KC, Muzzio IA, Rohrer D, Chruscinski A, Kobilka B, Kandel ER (1999) ERK plays a regulatory role in induction of LTP by theta frequency stimulation and its modulation by beta -adrenergic receptors. Neuron 24:715-726[Web of Science][Medline].
  • Xing J, Ginty DD, Greenberg ME (1996) Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 273:959-963[Abstract].
  • Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease [see comments]. Nature 382:685-691[Medline].
  • Zaman SH, Parent A, Laskey A, Lee MK, Borchelt DR, Sisodia SS, Malinow R (2000) Enhanced synaptic potentiation in transgenic mice expressing presenilin 1 familial Alzheimer's disease mutation is normalized with a benzodiazepine. Neurobiol Dis 7:54-63[Web of Science][Medline].

Copyright © 2001 Society for Neuroscience  0270-6474/01/21124125-09$05.00/0


This article has been cited by other articles:


Home page
 J. Neurosci.Home page
J. K. Knowles, J. Rajadas, T.-V. V. Nguyen, T. Yang, M. C. LeMieux, L. Vander Griend, C. Ishikawa, S. M. Massa, T. Wyss-Coray, and F. M. Longo
The p75 Neurotrophin Receptor Promotes Amyloid-{beta}(1-42)-Induced Neuritic Dystrophy In Vitro and In Vivo
J. Neurosci., August 26, 2009; 29(34): 10627 - 10637.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
G. Dziewczapolski, C. M. Glogowski, E. Masliah, and S. F. Heinemann
Deletion of the {alpha}7 Nicotinic Acetylcholine Receptor Gene Improves Cognitive Deficits and Synaptic Pathology in a Mouse Model of Alzheimer's Disease
J. Neurosci., July 8, 2009; 29(27): 8805 - 8815.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
M. D. Ikonomovic, L. Wecker, E. E. Abrahamson, J. Wuu, S. E. Counts, S. D. Ginsberg, E. J. Mufson, and S. T. DeKosky
Cortical {alpha}7 Nicotinic Acetylcholine Receptor and {beta}-Amyloid Levels in Early Alzheimer Disease
Arch Neurol, May 1, 2009; 66(5): 646 - 651.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
S. D. Buckingham, A. K. Jones, L. A. Brown, and D. B. Sattelle
Nicotinic Acetylcholine Receptor Signalling: Roles in Alzheimer's Disease and Amyloid Neuroprotection
Pharmacol. Rev., March 1, 2009; 61(1): 39 - 61.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Onozuka, A. Nakajima, K. Matsuzaki, R.-W. Shin, K. Ogino, D. Saigusa, N. Tetsu, A. Yokosuka, Y. Sashida, Y. Mimaki, et al.
Nobiletin, a Citrus Flavonoid, Improves Memory Impairment and A{beta} Pathology in a Transgenic Mouse Model of Alzheimer's Disease
J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 739 - 744.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J. A. Dickinson, J. N. C. Kew, and S. Wonnacott
Presynaptic {alpha}7- and {beta}2-Containing Nicotinic Acetylcholine Receptors Modulate Excitatory Amino Acid Release from Rat Prefrontal Cortex Nerve Terminals via Distinct Cellular Mechanisms
Mol. Pharmacol., August 1, 2008; 74(2): 348 - 359.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
E. Sturchler, A. Galichet, M. Weibel, E. Leclerc, and C. W. Heizmann
Site-Specific Blockade of RAGE-Vd Prevents Amyloid-{beta} Oligomer Neurotoxicity
J. Neurosci., May 14, 2008; 28(20): 5149 - 5158.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
R Carson, D Craig, B McGuinness, J A Johnston, F A O'Neill, A P Passmore, and C W Ritchie
{alpha}7 Nicotinic acetylcholine receptor gene and reduced risk of Alzheimer's disease
J. Med. Genet., April 1, 2008; 45(4): 244 - 248.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
S. E. Counts, B. He, S. Che, M. D. Ikonomovic, S. T. DeKosky, S. D. Ginsberg, and E. J. Mufson
{alpha}7 Nicotinic Receptor Up-regulation in Cholinergic Basal Forebrain Neurons in Alzheimer Disease
Arch Neurol, December 1, 2007; 64(12): 1771 - 1776.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Townsend, T. Mehta, and D. J. Selkoe
Soluble Abeta Inhibits Specific Signal Transduction Cascades Common to the Insulin Receptor Pathway
J. Biol. Chem., November 16, 2007; 282(46): 33305 - 33312.
[Abstract] [Full Text] [PDF]

Home page
 Learn. Mem.Home page
R. A. Countryman and P. E. Gold
Rapid forgetting of social transmission of food preferences in aged rats: Relationship to hippocampal CREB activation
Learn. Mem., May 3, 2007; 14(5): 350 - 358.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Tresini, A. Lorenzini, C. Torres, and V. J. Cristofalo
Modulation of Replicative Senescence of Diploid Human Cells by Nuclear ERK Signaling
J. Biol. Chem., February 9, 2007; 282(6): 4136 - 4151.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
Q. Liu, J. Zhang, H. Zhu, C. Qin, Q. Chen, and B. Zhao
Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model
FASEB J, January 1, 2007; 21(1): 61 - 73.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. M. Isaacs, D. B. Senn, M. Yuan, J. P. Shine, and B. A. Yankner
Acceleration of Amyloid beta-Peptide Aggregation by Physiological Concentrations of Calcium
J. Biol. Chem., September 22, 2006; 281(38): 27916 - 27923.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. H. Chong, Y. J. Shin, E. O. Lee, R. Kayed, C. G. Glabe, and A. J. Tenner
ERK1/2 Activation Mediates Abeta Oligomer-induced Neurotoxicity via Caspase-3 Activation and Tau Cleavage in Rat Organotypic Hippocampal Slice Cultures
J. Biol. Chem., July 21, 2006; 281(29): 20315 - 20325.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
C. Priller, T. Bauer, G. Mitteregger, B. Krebs, H. A. Kretzschmar, and J. Herms
Synapse formation and function is modulated by the amyloid precursor protein.
J. Neurosci., July 5, 2006; 26(27): 7212 - 7221.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Unger, M. M. Svedberg, W.-F. Yu, M. M. Hedberg, and A. Nordberg
Effect of Subchronic Treatment of Memantine, Galantamine, and Nicotine in the Brain of Tg2576 (APPswe) Transgenic Mice
J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 30 - 36.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
J. H. Park, D. A. Gimbel, T. GrandPre, J.-K. Lee, J.-E. Kim, W. Li, D. H. S. Lee, and S. M. Strittmatter
Alzheimer Precursor Protein Interaction with the Nogo-66 Receptor Reduces Amyloid-beta Plaque Deposition
J. Neurosci., February 1, 2006; 26(5): 1386 - 1395.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
J. Magrane, K. M. Rosen, R. C. Smith, K. Walsh, G. K. Gouras, and H. W. Querfurth
Intraneuronal {beta}-Amyloid Expression Downregulates the Akt Survival Pathway and Blunts the Stress Response
J. Neurosci., November 23, 2005; 25(47): 10960 - 10969.
[Abstract] [Full Text] [PDF]

Home page
 Learn. Mem.Home page
J. C. Pych, Q. Chang, C. Colon-Rivera, R. Haag, and P. E. Gold
Acetylcholine release in the hippocampus and striatum during place and response training
Learn. Mem., November 1, 2005; 12(6): 564 - 572.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
J. Chin, J. J. Palop, J. Puolivali, C. Massaro, N. Bien-Ly, H. Gerstein, K. Scearce-Levie, E. Masliah, and L. Mucke
Fyn Kinase Induces Synaptic and Cognitive Impairments in a Transgenic Mouse Model of Alzheimer's Disease
J. Neurosci., October 19, 2005; 25(42): 9694 - 9703.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
D. Puzzo, O. Vitolo, F. Trinchese, J. P. Jacob, A. Palmeri, and O. Arancio
Amyloid-{beta} Peptide Inhibits Activation of the Nitric Oxide/cGMP/cAMP-Responsive Element-Binding Protein Pathway during Hippocampal Synaptic Plasticity
J. Neurosci., July 20, 2005; 25(29): 6887 - 6897.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. Banerjee, G. Samoriski, and S. Gupta
Comments on "Memantine Blocks {alpha}7* Nicotinic Acetylcholine Receptors More Potently Than N-Methyl-D-aspartate Receptors in Rat Hippocampal Neurons"
J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 928 - 929.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Aracava, E. F. R. Pereira, A. Maelicke, and E. X. Albuquerque
Response: Comments on "Memantine Blocks {alpha}7* Nicotinic Acetylcholine Receptors More Potently Than N-Methyl-D-aspartate Receptors in Rat Hippocampal Neurons"
J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 930 - 933.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Oddo, A. Caccamo, K. N. Green, K. Liang, L. Tran, Y. Chen, F. M. Leslie, and F. M. LaFerla
Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease
PNAS, February 22, 2005; 102(8): 3046 - 3051.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S. L. Lambourne, L. A. Sellers, T. G. Bush, S. K. Choudhury, P. C. Emson, Y.-H. Suh, and L. S. Wilkinson
Increased tau Phosphorylation on Mitogen-Activated Protein Kinase Consensus Sites and Cognitive Decline in Transgenic Models for Alzheimer's Disease and FTDP-17: Evidence for Distinct Molecular Processes Underlying tau Abnormalities
Mol. Cell. Biol., January 1, 2005; 25(1): 278 - 293.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
D. L. Herber, E. G. Severance, J. Cuevas, D. Morgan, and M. N. Gordon
Biochemical and Histochemical Evidence of Nonspecific Binding of {alpha}7nAChR Antibodies to Mouse Brain Tissue
J. Histochem. Cytochem., October 1, 2004; 52(10): 1367 - 1376.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
E. C. C. Cheung and R. S. Slack
Emerging Role for ERK as a Key Regulator of Neuronal Apoptosis
Sci. Signal., September 21, 2004; 2004(251): pe45 - pe45.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
L. Tong, R. Balazs, P. L. Thornton, and C. W. Cotman
{beta}-Amyloid Peptide at Sublethal Concentrations Downregulates Brain-Derived Neurotrophic Factor Functions in Cultured Cortical Neurons
J. Neurosci., July 28, 2004; 24(30): 6799 - 6809.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
J. Chin, J. J. Palop, G.-Q. Yu, N. Kojima, E. Masliah, and L. Mucke
Fyn Kinase Modulates Synaptotoxicity, But Not Aberrant Sprouting, in Human Amyloid Precursor Protein Transgenic Mice
J. Neurosci., May 12, 2004; 24(19): 4692 - 4697.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
E. Wehrwein, S. A. Thompson, S. F. Coulibaly, D. M. Linn, and C. L. Linn
Acetylcholine Protection of Adult Pig Retinal Ganglion Cells from Glutamate-Induced Excitotoxicity
Invest. Ophthalmol. Vis. Sci., May 1, 2004; 45(5): 1531 - 1543.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. B. Marrero, R. L. Papke, B. S. Bhatti, S. Shaw, and M. Bencherif
The Neuroprotective Effect of 2-(3-Pyridyl)-1-azabicyclo[3.2.2]nonane (TC-1698), a Novel {alpha}7 Ligand, Is Prevented through Angiotensin II Activation of a Tyrosine Phosphatase
J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 16 - 27.
[Abstract] [Full Text]

Home page
 J. Neurosci.Home page
Q. Wang, D. M. Walsh, M. J. Rowan, D. J. Selkoe, and R. Anwyl
Block of Long-Term Potentiation by Naturally Secreted and Synthetic Amyloid {beta}-Peptide in Hippocampal Slices Is Mediated via Activation of the Kinases c-Jun N-Terminal Kinase, Cyclin-Dependent Kinase 5, and p38 Mitogen-Activated Protein Kinase as well as Metabotropic Glutamate Receptor Type 5
J. Neurosci., March 31, 2004; 24(13): 3370 - 3378.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
F. A. Dajas-Bailador, K. Heimala, and S. Wonnacott
The Allosteric Potentiation of Nicotinic Acetylcholine Receptors by Galantamine Is Transduced into Cellular Responses in Neurons: Ca2+ Signals and Neurotransmitter Release.
Mol. Pharmacol., November 1, 2003; 64(5): 1217 - 1226.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
E. O Mann and S. A Greenfield
Novel modulatory mechanisms revealed by the sustained application of nicotine in the guinea-pig hippocampus in vitro
J. Physiol., September 1, 2003; 551(2): 539 - 550.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H.-Y. Wang, W. Li, N. J. Benedetti, and D. H. S. Lee
{alpha}7 Nicotinic Acetylcholine Receptors Mediate {beta}-Amyloid Peptide-induced Tau Protein Phosphorylation
J. Biol. Chem., August 22, 2003; 278(34): 31547 - 31553.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. J. Palop, B. Jones, L. Kekonius, J. Chin, G.-Q. Yu, J. Raber, E. Masliah, and L. Mucke
Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits
PNAS, August 5, 2003; 100(16): 9572 - 9577.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
J. J. Dougherty, J. Wu, and R. A. Nichols
{beta}-Amyloid Regulation of Presynaptic Nicotinic Receptors in Rat Hippocampus and Neocortex
J. Neurosci., July 30, 2003; 23(17): 6740 - 6747.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
C. A. Dickey, J. F. Loring, J. Montgomery, M. N. Gordon, P. S. Eastman, and D. Morgan
Selectively Reduced Expression of Synaptic Plasticity-Related Genes in Amyloid Precursor Protein + Presenilin-1 Transgenic Mice
J. Neurosci., June 15, 2003; 23(12): 5219 - 5226.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
M. E. Bamberger, M. E. Harris, D. R. McDonald, J. Husemann, and G. E. Landreth
A Cell Surface Receptor Complex for Fibrillar beta -Amyloid Mediates Microglial Activation
J. Neurosci., April 1, 2003; 23(7): 2665 - 2674.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
F. Grassi, E. Palma, R. Tonini, M. Amici, M. Ballivet, and F. Eusebi
Amyloid {beta}1-42 peptide alters the gating of human and mouse {alpha}-bungarotoxin-sensitive nicotinic receptors
J. Physiol., February 15, 2003; 547(1): 147 - 157.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Dobransky, D. Brewer, G. Lajoie, and R. J. Rylett
Phosphorylation of 69-kDa Choline Acetyltransferase at Threonine 456 in Response to Amyloid-beta Peptide 1-42
J. Biol. Chem., February 14, 2003; 278(8): 5883 - 5893.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Shaw, M. Bencherif, and M. B. Marrero
Janus Kinase 2, an Early Target of alpha 7 Nicotinic Acetylcholine Receptor-mediated Neuroprotection against Abeta -(1-42) Amyloid
J. Biol. Chem., November 15, 2002; 277(47): 44920 - 44924.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
E. J. Weeber, J. M. Levenson, and J. D. Sweatt
Molecular Genetics of Human Cognition
Mol. Interv., October 1, 2002; 2(6): 376 - 391.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
T. D. Stein and J. A. Johnson
Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein Is Associated with Increased Levels of Transthyretin and the Activation of Cell Survival Pathways
J. Neurosci., September 1, 2002; 22(17): 7380 - 7388.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. T. Dineley, K. A. Bell, D. Bui, and J. D. Sweatt
beta -Amyloid Peptide Activates alpha 7 Nicotinic Acetylcholine Receptors Expressed in Xenopus Oocytes
J. Biol. Chem., July 5, 2002; 277(28): 25056 - 25061.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. T. Dineley, X. Xia, D. Bui, J. D. Sweatt, and H. Zheng
Accelerated Plaque Accumulation, Associative Learning Deficits, and Up-regulation of alpha 7 Nicotinic Receptor Protein in Transgenic Mice Co-expressing Mutant Human Presenilin 1 and Amyloid Precursor Proteins
J. Biol. Chem., June 14, 2002; 277(25): 22768 - 22780.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
M. J. Savage, Y.-G. Lin, J. R. Ciallella, D. G. Flood, and R. W. Scott
Activation of c-Jun N-Terminal Kinase and p38 in an Alzheimer's Disease Model Is Associated with Amyloid Deposition
J. Neurosci., May 1, 2002; 22(9): 3376 - 3385.
[Abstract] [Full Text] [PDF]

Home page
 Behav Cogn Neurosci RevHome page
D. S. Woodruff-Pak and T. J. Gould
Neuronal nicotinic acetylcholine receptors: involvement in Alzheimer's disease and schizophrenia.
Behav Cogn Neurosci Rev, March 1, 2002; 1(1): 5 - 20.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (220)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dineley, K. T.
Right arrow Articles by Sweatt, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dineley, K. T.
Right arrow Articles by Sweatt, J. D.

-
-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help
-
Copyright 2009 by Society for Neuroscience ONLINE ISSN: 1529-2401
-